RLAY

#1501
Relay Therapeutics, Inc. - Common Stock
18.3 8 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
18.34
18.38
Intervallo Annuale
3.57
21.27
Variazione giornaliera
-2.08%
Variazione Mensile
-1.13%
Variazione di 6 mesi
+85.47%
Variazione Annuale
+413.41%
Chiusura Precedente
18.7 7
Open
18.3 4
Minimo
18.3 4
Massimo
18.3 8
Volume
146
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Relay Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Relay Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Relay Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Relay Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Relay Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Relay Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Relay Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Relay Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Relay Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Relay Therapeutics, Inc. current report, Q1 FY2026
8-K

Relay Therapeutics, Inc. current report, Q2 FY2021

Full document

Relay Therapeutics, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Relay Therapeutics, Inc. on May 19, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Cambridge, Massachusetts. The filing details the voting results for two proposals submitted to security holders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.

Material Changes and Voting Results

The following proposals were voted upon at the Annual Meeting:

  • Proposal 1: Election of Directors
    • Sanjiv K. Patel, M.D.: Elected with 58,131,314 votes for, 6,738,675 votes withheld, and 11,108,400 broker non-votes.
    • Linda A. Hill, Ph.D.: Elected with 55,066,632 votes for, 9,803,357 votes withheld, and 11,108,400 broker non-votes.
    • Both directors were elected to a three-year term ending at the 2024 annual meeting.
  • Proposal 2: Ratification of Independent Auditor
    • Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
    • Votes cast: 75,969,543 for, 5,958 against, 2,888 abstain, and 0 broker non-votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No other matters were submitted to or voted on by stockholders at the meeting.

Investor Verification Checklist

  • Verify the full composition of the Board of Directors following the election of Class I directors.
  • Review the Definitive Proxy Statement on Schedule 14A (filed April 7, 2021) for detailed biographies of the elected directors and the rationale for the auditor appointment.
  • Confirm the total number of shares outstanding and voting rights structure to contextualize the vote counts.

Notizie